Nanogen Licenses Gene Variants from Pathway Diagnostics for Dx Predicting Drug Response | GenomeWeb

NEW YORK, March 22 (GenomeWeb News) - Nanogen has licensed genetic variations from Pathways Diagnostics that predict patients' response to antidepressants and antipsychotic in order to create a diagnostic product, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.